Company intelligence
IMA Clinical Research
About IMA Clinical Research
Our clinical research network is a collaborative group of providers and sites dedicated to clinical research across multiple therapeutic areas. When sponsors and CROs join our nationwide network, they immediately gain access to diverse patient populations in both cities and underserved locations and the innovative tools needed to accelerate enrollment, support patients during trials, improve retention, and enhance data and understanding. Additionally, we use a modern, tech-enabled operating model to deliver various study designs, including classic site-based, hybrid and fully decentralized trials. The IMA Clinical Research Network: • 15+ Full-Service Clinical Trial Sites • 180+ Nationwide Satellite Sites • 10K+ Unique Weekly Visits • 400K+ Patient Database To learn more about IMA Clinical Research, visit imaresearch.com
Verified activity
Signals from IMA Clinical Research
6 published signals
Presence & Recognition
IMA Clinical Research is hosting a SCRS webinar titled Measure What Matters: Building KPIs That Reflect the Real Work of Clinical Research on September 15 at 12 p.m. ET featuring Dana Poff, Sean Cunningham, and Karen McIntyre.
Reported by IMA Clinical Research
Presence & Recognition
IMA Clinical Research reached 10,000+ followers and is growing.
Reported by IMA Clinical Research
Presence & Recognition
IMA Clinical Research is preparing for the Society for Clinical Research Sites (SCRS) Global Site Solutions Summit in Orlando.
Reported by IMA Clinical Research
Research & Knowledge
IMA Clinical Research is involved in clinical trials to better understand mental health conditions and advance potential new treatments.
Reported by Olivia Bochel MHA
Presence & Recognition
IMA Clinical Research is hosting a webinar on September 15 titled Measure What Matters: Building KPIs That Reflect the Real Work of Clinical Research, featuring Dana Poff, Sean Cunningham, and Karen McIntyre.
Reported by IMA Clinical Research
Legal & Regulatory
IMA Clinical Research sites across the nationwide site network contributed to the Phase 3 mRNA-1010-P304 (Fluent) Trial, whose results supported the approval of Moderna’s mFLUSIVA® for adults 50 years and older by the FDA.
Reported by IMA Clinical Research